00:46 , Aug 4, 2018 |  BioCentury  |  Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
23:14 , Jun 29, 2018 |  BC Extra  |  Financial News

I-Mab continues trend of large Chinese-led venture rounds

I-Mab Biopharma (Shanghai, China) raised $220 million Friday in a series C round led by Hony Capital, making it at least the fourth $200 million-plus VC round led by Chinese investors in the past two...
23:59 , Jun 21, 2018 |  BC Innovations  |  Product R&D

Tusk’s take on CD25

As companies revisit the potential of IL-2 to aid cancer immunotherapy, Tusk Therapeutics Ltd. has a new take by attacking CD25, a component of the IL-2 receptor with its own storied past. Its antibody could...
18:02 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Genmab, Janssen discontinue Darzalex combo trials

Genmab A/S (CSE:GEN; Pink:GMXAY) said partner Janssen Biotech Inc. will discontinue two studies of Darzalex daratumumab in combination with different immune checkpoint inhibitors. The studies include the open-label, international Phase Ib/II CALLISTO/LUC2001 trial, which is evaluating...
05:12 , May 29, 2018 |  BC Extra  |  Clinical News

Genmab slides as Darzalex combo trials discontinued

Genmab A/S (CSE:GEN; Pink:GMXAY) sank DKK239.30 (20%) to DKK953.20 in Copenhagen on Monday after it said partner Janssen Biotech Inc. will discontinue two studies of Darzalex daratumumab in combination with different immune checkpoint inhibitors. The studies...
21:46 , Apr 17, 2018 |  BC Extra  |  Company News

J&J reports strong Darzalex sales, discontinues antibiotic

Johnson & Johnson (NYSE:JNJ) reported 1Q18 earnings, including stronger-than-expected sales of Darzalex daratumumab, and raised its full-year sales guidance. The company now expects 2018 sales of $81.0-$81.9 billion, up from $80.6-$81.4 billion. Sales of Darzalex were...
22:06 , Feb 23, 2018 |  BC Extra  |  Company News

Darzalex guidance buoys Genmab shares

Genmab A/S (CSE:GEN; Pink:GMXAY) gained DKK13.6 billion ($2.3 billion) in market cap across two days of trading after issuing an earnings report that included new 2018 guidance for multiple myeloma (MM) drug Darzalex daratumumab. Based...
01:19 , Feb 16, 2018 |  BC Innovations  |  Product R&D

Banking on the placenta

Celgene Corp. spinout Celularity Inc. is aiming to disrupt the stem cell market with a platform of placenta-based cell therapies whose intrinsic allo-tolerance could provide a broadly applicable system for propelling off-the-shelf cancer therapies into...
01:40 , Jan 27, 2018 |  BioCentury  |  Strategy

Growing up Genzyme

The proposed acquisition of Bioverativ Inc. ticks multiple boxes on Sanofi’s to-do list for transforming itself into a top tier pharma, and solidifies the position of its Genzyme unit as the pharma’s growth engine. Olivier Brandicourt...
16:20 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

FDA grants Darzalex Priority Review for first-line MM

Genmab A/S (CSE:GEN; Pink:GMXAY) said FDA accepted and granted Priority Review to an sBLA from partner Johnson & Johnson (NYSE:JNJ) for Darzalex daratumumab to treat multiple myeloma in the first-line setting. The PDUFA date is...